Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody

Nimisha Deb, Michael Goris, Kirk Trisler, Sherry Fowler, Jeannette Saal, Shoucheng Ning, Mark Becker, Carol Marquez, Susan Knox

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58% had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 111In and 90Y-CYT-356 were tolerated well, without significant nonhematological toxicity. Myelosuppression was the dose-limiting toxicity and occurred at dose levels of 4.5-12 mCi/m2. Of the patients receiving ≤9 mCi/m2, 55% had grade 1 or 2 leukopenia and/or thrombocytopenia. Two of three patients treated with 12 mCi/m2 experienced grade 3 thrombocytopenia and leukopenia. One patient treated with 12 mCi/m2 had grade 4 neutropenia. The maximum tolerated dose of 90Y-CYT-356 was 9 mCi/m2. Only one patient developed a human anti-mouse antibody 4 weeks after treatment. No patient attained a complete or partial response based on prostate-specific antigen and/or radiological criteria. Three patients had transient subjective improvement in the symptomatology of their disease. In addition, patients treated with 12 mCi/m2 of 90Y-CYT-356 had a slightly longer freedom from disease progression than patients treated with doses of 90Y-CYT-356 ≤9 mCi/m2.

Original languageEnglish (US)
Pages (from-to)1289-1297
Number of pages9
JournalClinical Cancer Research
Volume2
Issue number8
StatePublished - Aug 1996

Fingerprint

Prostatic Neoplasms
Monoclonal Antibodies
Hormones
Therapeutics
Leukopenia
Capromab Pendetide
Maximum Tolerated Dose
Prostate-Specific Antigen
Neutropenia
Thrombocytopenia
Disease Progression
Prostate
Anti-Idiotypic Antibodies
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., Ning, S., ... Knox, S. (1996). Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clinical Cancer Research, 2(8), 1289-1297.

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. / Deb, Nimisha; Goris, Michael; Trisler, Kirk; Fowler, Sherry; Saal, Jeannette; Ning, Shoucheng; Becker, Mark; Marquez, Carol; Knox, Susan.

In: Clinical Cancer Research, Vol. 2, No. 8, 08.1996, p. 1289-1297.

Research output: Contribution to journalArticle

Deb, N, Goris, M, Trisler, K, Fowler, S, Saal, J, Ning, S, Becker, M, Marquez, C & Knox, S 1996, 'Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody', Clinical Cancer Research, vol. 2, no. 8, pp. 1289-1297.
Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clinical Cancer Research. 1996 Aug;2(8):1289-1297.
Deb, Nimisha ; Goris, Michael ; Trisler, Kirk ; Fowler, Sherry ; Saal, Jeannette ; Ning, Shoucheng ; Becker, Mark ; Marquez, Carol ; Knox, Susan. / Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 8. pp. 1289-1297.
@article{7b947de8c276451fbbe6c184e146bb73,
title = "Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody",
abstract = "A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58{\%} had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 111In and 90Y-CYT-356 were tolerated well, without significant nonhematological toxicity. Myelosuppression was the dose-limiting toxicity and occurred at dose levels of 4.5-12 mCi/m2. Of the patients receiving ≤9 mCi/m2, 55{\%} had grade 1 or 2 leukopenia and/or thrombocytopenia. Two of three patients treated with 12 mCi/m2 experienced grade 3 thrombocytopenia and leukopenia. One patient treated with 12 mCi/m2 had grade 4 neutropenia. The maximum tolerated dose of 90Y-CYT-356 was 9 mCi/m2. Only one patient developed a human anti-mouse antibody 4 weeks after treatment. No patient attained a complete or partial response based on prostate-specific antigen and/or radiological criteria. Three patients had transient subjective improvement in the symptomatology of their disease. In addition, patients treated with 12 mCi/m2 of 90Y-CYT-356 had a slightly longer freedom from disease progression than patients treated with doses of 90Y-CYT-356 ≤9 mCi/m2.",
author = "Nimisha Deb and Michael Goris and Kirk Trisler and Sherry Fowler and Jeannette Saal and Shoucheng Ning and Mark Becker and Carol Marquez and Susan Knox",
year = "1996",
month = "8",
language = "English (US)",
volume = "2",
pages = "1289--1297",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody

AU - Deb, Nimisha

AU - Goris, Michael

AU - Trisler, Kirk

AU - Fowler, Sherry

AU - Saal, Jeannette

AU - Ning, Shoucheng

AU - Becker, Mark

AU - Marquez, Carol

AU - Knox, Susan

PY - 1996/8

Y1 - 1996/8

N2 - A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58% had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 111In and 90Y-CYT-356 were tolerated well, without significant nonhematological toxicity. Myelosuppression was the dose-limiting toxicity and occurred at dose levels of 4.5-12 mCi/m2. Of the patients receiving ≤9 mCi/m2, 55% had grade 1 or 2 leukopenia and/or thrombocytopenia. Two of three patients treated with 12 mCi/m2 experienced grade 3 thrombocytopenia and leukopenia. One patient treated with 12 mCi/m2 had grade 4 neutropenia. The maximum tolerated dose of 90Y-CYT-356 was 9 mCi/m2. Only one patient developed a human anti-mouse antibody 4 weeks after treatment. No patient attained a complete or partial response based on prostate-specific antigen and/or radiological criteria. Three patients had transient subjective improvement in the symptomatology of their disease. In addition, patients treated with 12 mCi/m2 of 90Y-CYT-356 had a slightly longer freedom from disease progression than patients treated with doses of 90Y-CYT-356 ≤9 mCi/m2.

AB - A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58% had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 111In and 90Y-CYT-356 were tolerated well, without significant nonhematological toxicity. Myelosuppression was the dose-limiting toxicity and occurred at dose levels of 4.5-12 mCi/m2. Of the patients receiving ≤9 mCi/m2, 55% had grade 1 or 2 leukopenia and/or thrombocytopenia. Two of three patients treated with 12 mCi/m2 experienced grade 3 thrombocytopenia and leukopenia. One patient treated with 12 mCi/m2 had grade 4 neutropenia. The maximum tolerated dose of 90Y-CYT-356 was 9 mCi/m2. Only one patient developed a human anti-mouse antibody 4 weeks after treatment. No patient attained a complete or partial response based on prostate-specific antigen and/or radiological criteria. Three patients had transient subjective improvement in the symptomatology of their disease. In addition, patients treated with 12 mCi/m2 of 90Y-CYT-356 had a slightly longer freedom from disease progression than patients treated with doses of 90Y-CYT-356 ≤9 mCi/m2.

UR - http://www.scopus.com/inward/record.url?scp=0029737680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029737680&partnerID=8YFLogxK

M3 - Article

C2 - 9816299

AN - SCOPUS:0029737680

VL - 2

SP - 1289

EP - 1297

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -